In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since…
In Conversation
Michael Sean Reilly: General Manager for Pharmaceuticals Juan Carlos Berbessi: Medical Director Maria del Pilar Rubio: Medical Manager for Vaccines Gustavo Zapata: Finance Director Juan Pablo…
There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a…
What is the role, significance, and importance of the Colombian market within the larger global strategy of Genzyme international? Colombia is a very important country because…
Diabetes affects an estimated 6 million Brazilians, a figure which is expected to double by 2025, in line with many other developing nations. Like many other…
What has been the evolution of Roche’s operations in Colombia’s over the course of its proud 52-year history here? As with almost all pharmaceutical companies with…
When we interviewed you four years ago, you gave us a picture of the industry. How has that picture changed since then? We can start with…
Having just recently celebrated its 50th anniversary in Colombia, how would you describe Farma de Colombia’s unique business model and what have been its keys to…
An important topic in Brazil is access to drugs. In recent interviews we have spoken about a third of MS patients being treated, or 10% of…
Yesterday the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the…
10 days ago, your Swedish counterpart Mats Larsson made a technical visit here at ANVISA and said he had a lot to learn. What is it…
Yesterday, Minister Pimentel unveiled the Brazil Maior plan to increase competitiveness and growth across a variety of industrial sectors. If you had to give recommendations to…
